share_log

EF Hutton Maintains Buy on Pasithea Therapeutics, Lowers Price Target to $2

EF Hutton Maintains Buy on Pasithea Therapeutics, Lowers Price Target to $2

EF Hutton 維持對Pasithea Therapeutics的買入,將目標價下調至2美元
Benzinga ·  2023/04/03 10:01

EF Hutton analyst Constantine Davides maintains Pasithea Therapeutics (NASDAQ:KTTA) with a Buy and lowers the price target from $2.3 to $2.

EF Hutton分析師康斯坦丁·戴維斯維持Pasithea Therapeutics(納斯達克股票代碼:KTTA)的買入,並將目標股價從2.3美元下調至2美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論